Avicena Group to Present at 10th Annual BIO CEO & Investor Conference
February 07 2008 - 2:26PM
PR Newswire (US)
PALO ALTO, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Avicena Group,
Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a late-stage biotechnology
company that develops central nervous system therapeutics for
neurodegenerative disorders, announced today that chairman and
chief executive officer, Belinda Tsao Nivaggioli, Ph.D., will
present an overview of the company's ongoing clinical development
programs at the 10th Annual BIO CEO & Investor Conference to be
held February 11-13, 2008 at the Waldorf Astoria Hotel in New York
City. Dr. Tsao Nivaggioli will be presenting on Monday, February 11
at 12:30 p.m. (ET) in the East Foyer. For more information on this
event please visit:
http://ceo.bio.org/opencms/ceo/2008/about/index.jsp To participate
in a live audio webcast of Dr. Tsao Nivaggioli's presentation
please log onto Avicena's corporate website at
http://www.avicenagroup.com/ at least fifteen minutes prior to the
start of the presentation to download any necessary materials. An
archive of this event will be available in the investor relations
section of the website for 90 days. ABOUT AVICENA Avicena Group,
Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) is a Palo Alto, California
based late-stage biotechnology company that develops central
nervous system therapeutics for neurodegenerative disorders. The
company's core technologies, supported by a robust IP portfolio,
have broad applications in both pharmaceuticals and dermaceuticals.
Avicena's pharmaceutical program centers on rare neurological
disorders (orphan diseases). Near term, the company plans to
initiate a confirmatory Phase III trial in ALS and a Phase III
trial in Huntington's disease to accompany the ongoing NIH Phase
III trial in Parkinson's disease. Avicena's science is well
established and its products are safe and well tolerated. Unlike
traditional biotechnology companies, Avicena's clinical programs
are largely funded by government and non-profit organizations.
Avicena presently derives revenue from the sale of proprietary
dermaceutical ingredients to skin care manufacturers. SAFE HARBOR
This release contains forward-looking statements that reflect,
among other things, management's current expectations, plans and
strategies, all of which are subject to known and unknown risks,
uncertainties and factors that may cause our actual results to
differ materially from those expressed or implied by these
forward-looking statements. Many of these risks are beyond our
ability to control or predict. See "Risk Factors" under "Item 6.
Management's Discussion and Analysis of Financial Condition and
Results of Operation" from our Annual Report on Form 10-KSB for the
year ended December 31, 2006, and other descriptions in the
company's public filings with the Securities and Exchange
Commission for a discussion of such risks, including the company's
need for additional funds, the company's dependence on a limited
number of therapeutic compounds, the stage of the products the
company is developing, uncertainties relating to clinical trials
and regulatory reviews, competition and dependence on collaborative
partners, the company's ability to avoid infringement of the patent
rights of others, and the company's ability to obtain adequate
patent protection and to enforce these rights. Because of these
risks, uncertainties and assumptions, you should not place undue
reliance on these forward-looking statements. Furthermore,
forward-looking statements speak only as of the date they are made.
Avicena does not undertake any obligation to update or review any
such forward-looking information, whether as a result of new
information, future events or otherwise. Contact: The Ruth Group
(on behalf of Avicena Group) Sara Ephraim (investors) (646)
536-7002 Janine McCargo / Jason Rando (media) (646) 536-7033 / 7025
or DATASOURCE: Avicena Group, Inc. CONTACT: investors, Sara
Ephraim, +1-646-536-7002, , or Janine McCargo, +1-646-536-7033, ,
or media, Jason Rando, +1-646-536-7025, , all of The Ruth Group for
Avicena Group, Inc. Web site: http://www.avicenagroup.com/
http://ceo.bio.org/opencms/ceo/2008/about/index.jsp
Copyright